Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 20.2 USD 2.96% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Viridian Therapeutics Inc?
Write Note

Viridian Therapeutics Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Viridian Therapeutics Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Viridian Therapeutics Inc
NASDAQ:VRDN
Total Equity
$707.5m
CAGR 3-Years
51%
CAGR 5-Years
98%
CAGR 10-Years
58%
Abbvie Inc
NYSE:ABBV
Total Equity
$6B
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Total Equity
$18.4B
CAGR 3-Years
-5%
CAGR 5-Years
-2%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Total Equity
$7.5B
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
-11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Equity
$15.6B
CAGR 3-Years
18%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Equity
$29.3B
CAGR 3-Years
19%
CAGR 5-Years
23%
CAGR 10-Years
28%
No Stocks Found

Viridian Therapeutics Inc
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 86 full-time employees. The company went IPO on 2014-06-18. The firm is engaged in developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that is developed for intravenous (IV) or subcutaneous administration to treat patients who suffer from thyroid eye disease (TED). Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. The company has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED. VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001.

VRDN Intrinsic Value
7.68 USD
Overvaluation 62%
Intrinsic Value
Price

See Also

What is Viridian Therapeutics Inc's Total Equity?
Total Equity
707.5m USD

Based on the financial report for Sep 30, 2024, Viridian Therapeutics Inc's Total Equity amounts to 707.5m USD.

What is Viridian Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 10Y
58%

Over the last year, the Total Equity growth was 149%. The average annual Total Equity growth rates for Viridian Therapeutics Inc have been 51% over the past three years , 98% over the past five years , and 58% over the past ten years .

Back to Top